Sorafenib tosylate novel drug delivery systems: Implications of nanotechnology in both approved and unapproved indications
The USFDA has approved sorafenib tosylate for the treatment of thyroid cancer, kidney cancer, and hepatocellular carcinoma. Conventional formulations of sorafenib tosylate have challenges of solubility, permeability, side effects, and drug resistance across cancer cells. Targeted cancer therapies ba...
Saved in:
Main Authors: | Hrushikesh Raut (Author), Chetana Jadhav (Author), Karishma Shetty (Author), Neha Laxane (Author), Harsh P. Nijhawan (Author), GSN Koteswara Rao (Author), Rajasekhar Reddy Alavala (Author), Garima Joshi (Author), Ch. Niranjan Patro (Author), Govind Soni (Author), Khushwant S. Yadav (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2022-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Improving anti-tumor activity of sorafenib tosylate by lipid- and polymer-coated nanomatrix
by: Yang Guo, et al.
Published: (2017) -
Structural Polymorphism of Sorafenib Tosylate as a Key Factor in Its Solubility Differentiation
by: Gabriela Wiergowska, et al.
Published: (2021) -
Sorafenib tosylate for advanced kidney cancer: lucky loser and magic box at the same time
by: Camillo Porta
Published: (2011) -
Stability indicating Rp-UPLC method development and validation for the simultaneous estimation of fosnetupitant and palonosetron in bulk and injection dosage form
by: Poojari Venkatesh, et al.
Published: (2022) -
Subconjunctival Delivery of Sorafenib-Tosylate-Loaded Cubosomes for Facilitated Diabetic Retinopathy Treatment: Formulation Development, Evaluation, Pharmacokinetic and Pharmacodynamic (PKPD) Studies
by: Sharadha Madhusudhan, et al.
Published: (2023)